(HealthDay News) – Metoclopramide use during pregnancy for nausea is not associated with an increased risk of birth defects, spontaneous abortion, or stillbirth, according to a study published in the Oct. 16 issue of the Journal of the American Medical Association.
Björn Pasternak, MD, PhD, from the Statens Serum Institut in Copenhagen, Denmark, and colleagues compared outcomes based on metoclopramide exposure during pregnancy among 1,222,503 pregnancies in Denmark.
The researchers found that 28,486 women were exposed to metoclopramide in the first trimester, with no significant association seen between metoclopramide use and major congenital malformations (prevalence odds ratio, 0.93) or any of the 20 individual malformation categories. There was also no association between metoclopramide and an increased risk of spontaneous abortion (hazard ratio, 0.35) or stillbirth (hazard ratio, 0.9).
“Metoclopramide use in pregnancy was not associated with increased risk of major congenital malformations overall, any of the 20 individual malformation categories assessed, spontaneous abortion, or stillbirth,” Pasternak and colleagues conclude.